Hepatocyte Nuclear Factor 4 Alpha (HNF4A) is a master nuclear receptor transcription factor key to hepatic development, metabolic homeostasis, and pancreatic beta-cell function. Mutations in HNF4A drive Maturity-Onset Diabetes of the Young Type 1 (MODY1), while its dysregulation is heavily implicated in Non-Alcoholic Steatohepatitis (NASH), liver cirrhosis, and gastrointestinal cancers. Targeting the HNF4A transcriptional network with small-molecule modulators (agonists for metabolic rescue; antagonists for oncology) represents a high-potential frontier in drug discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for HNF4A drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | HNF4A Recombinant Protein (Ligand Binding Domain / Full Length) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for ligand-binding assays (TR-FRET, FP). |
View HNF4A Products |
| Gene Delivery | HNF4A Lentivirus Premade Particles Full-length ORF for stable cell line generation and reporter gene assays. |
View HNF4A Products |
| Benchmark Ab | Anti-HNF4A Recombinant Antibody High-affinity positive control for Western Blot, ChIP, and IHC validation. |
View HNF4A Products |
| Validator | HNF4A siRNA Set Target-specific knockdown pool for functional validation in hepatocyte models. |
View HNF4A Products |
| Related Target A | HNF1A Downstream metabolic regulator. Co-segregates with HNF4A pathways in MODY and hepatic differentiation. |
View HNF1A Products |
| Related Target B | FOXA2 Pioneer transcription factor that cooperatively binds chromatin with HNF4A to initiate hepatic gene expression. |
View FOXA2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Nuclear Receptor Conformation & Stability | Purified HNF4A Ligand Binding Domain (LBD) containing endogenous fatty acid ligands, preserving structural integrity for biophysical assays. |
| Isoform-Specific Targeting (HNF4A1 vs HNF4A9) | Sequence-verified isoform-specific recombinant proteins and custom expression constructs. |
| Lack of Validated Control Reagents | Sequence-derived recombinant benchmark antibodies included for assay standardization. |
| Off-Target Transcriptional Profiling | Validated siRNA pools and control cell lines to rule out non-specific gene regulation. |
Live HNF4A R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of HNF4A is shifting from genetic characterization to active small-molecule modulation. Traditionally deemed "undruggable" due to its constitutively bound endogenous fatty acid ligands, modern drug discovery utilizes allosteric pocket targeting to either stabilize (agonists for NASH/liver failure) or disrupt (antagonists for colon/gastric cancers) HNF4A-mediated transcription. The next wave of R&D focuses on tissue-specific delivery systems (such as GalNAc conjugation or lipid nanoparticles) to target hepatocytes directly while avoiding systemic endocrine side effects.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Academic/Pharma Consortia | NASH, Cirrhosis, MODY1 | Ligand Binding Assays (Need high-purity LBD protein with theoretical MW verification) |
| Small Molecule Antagonist | Oncology-focused Biotechs | Colorectal Cancer, Gastric Cancer | Reporter Gene Assays (Need HNF4A Lentivirus for stable reporter line construction) |
| mRNA / Gene Therapy | Hepatic Regeneration Biotechs | Acute Liver Failure | Expression Validation (Need sequence-verified HNF4A antibodies & siRNA knockdown controls) |